Mary Wilson
New member
CanSino Biologics’s experimental COVID-19 vaccine is one of at least four using an adenovirus that some worry could increase HIV susceptibility.
CHINA DAILY CDIC / REUTERS
By Jon Cohen
Oct. 19, 2020 , 6:30 PM
Certain COVID-19 vaccine candidates could increase susceptibility to HIV, warns a group of researchers who in 2007 learned that an experimental HIV vaccine had raised in some people the risk for infection with the AIDS virus. These concerns have percolated in the background of the race for a vaccine to stem the coronavirus pandemic, but now the researchers have gone public with a “cautionary tale,” in part because trials of those candidates may soon begin in locales that have pronounced HIV epidemics, such as South Africa.
Some approved and experimental vaccines have as a backbone a variety of adenoviruses, which can cause the common cold but are often harmless. The ill-fated HIV vaccine trial used an engineered strain known as adenovirus 5 (Ad5) to shuttle into the body the gene for the surface protein of the AIDS virus. In four candidate COVID-19 vaccines now in clinical trials in several countries, including the United States, Ad5 similarly serves as the “vector” to carry in the surface protein gene of SARS-CoV-2, the viral cause of the pandemic; two of these have advanced to large-scale, phase III efficacy studies in Russia and Pakistan.
https://www.sciencemag.org/news/202...cines-leave-people-more-vulnerable-aids-virus
_________________________________________________________________________________________
Use of adenovirus type-5 vectored vaccines: a cautionary tale
Susan P Buchbinder, M Juliana McElrath, Carl Dieffenbach, Lawrence Corey
Published:October 19, 2020
DOI:https://doi.org/10.1016/S0140-6736(20)32156-5
We are writing to express concern about the use of a recombinant adenovirus type-5 (Ad5) vector for a COVID-19 phase 1 vaccine study,[SUP]1[/SUP] and subsequent advanced trials.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32156-5/fulltext
CHINA DAILY CDIC / REUTERS
By Jon Cohen
Oct. 19, 2020 , 6:30 PM
Certain COVID-19 vaccine candidates could increase susceptibility to HIV, warns a group of researchers who in 2007 learned that an experimental HIV vaccine had raised in some people the risk for infection with the AIDS virus. These concerns have percolated in the background of the race for a vaccine to stem the coronavirus pandemic, but now the researchers have gone public with a “cautionary tale,” in part because trials of those candidates may soon begin in locales that have pronounced HIV epidemics, such as South Africa.
Some approved and experimental vaccines have as a backbone a variety of adenoviruses, which can cause the common cold but are often harmless. The ill-fated HIV vaccine trial used an engineered strain known as adenovirus 5 (Ad5) to shuttle into the body the gene for the surface protein of the AIDS virus. In four candidate COVID-19 vaccines now in clinical trials in several countries, including the United States, Ad5 similarly serves as the “vector” to carry in the surface protein gene of SARS-CoV-2, the viral cause of the pandemic; two of these have advanced to large-scale, phase III efficacy studies in Russia and Pakistan.
https://www.sciencemag.org/news/202...cines-leave-people-more-vulnerable-aids-virus
_________________________________________________________________________________________
Use of adenovirus type-5 vectored vaccines: a cautionary tale
Susan P Buchbinder, M Juliana McElrath, Carl Dieffenbach, Lawrence Corey
Published:October 19, 2020
DOI:https://doi.org/10.1016/S0140-6736(20)32156-5
We are writing to express concern about the use of a recombinant adenovirus type-5 (Ad5) vector for a COVID-19 phase 1 vaccine study,[SUP]1[/SUP] and subsequent advanced trials.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32156-5/fulltext